Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy

Clinical Biochemistry

Volumn 44, Issue 4, 2011, Pages 307-311

  Lu, Jianxin ^a,b   Randell, Edward ^c   Han, YingChun ^c   Adeli, Khosrow ^d   Krahn, John ^b   Meng, Qing H ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adhesion molecules; Cytokines; Diabetes; Diabetic; Methylglyoxal; Nephropathy

Indexed keywords

ALBUMIN; CELL ADHESION MOLECULE; CREATININE; CYTOKINE; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 6; METHYLGLYOXAL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ALBUMINS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CREATININE; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PLASMA; PYRUVALDEHYDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79651470951     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.11.004     Document Type: Article

References (41)

1. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can. J. Diab. 2008, 32:S1-S201. Canadian Diabetes Association.
2. Klausen K., Borch-Johnsen K., Feldt-Rasmussen B., et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004, 110:32-35.
3. Kalapos M.P. Methylglyoxal in living organisms: chemistry, biochemistry, toxicology and biological implications. Toxicol. Lett. 1999, 110:145-175.
4. Nemet I., Turk Z., Duvnjak L., Car N., Varga-Defterdarovic L. Humoral methylglyoxal level reflects glycemic fluctuation. Clin. Biochem. 2005, 38:379-383.
5. Beisswenger P.J., Howell S.K., Touchette A.D., Lal S., Szwergold B.S. MG level was highly elevated in diabetic patients compared with the normal controls. Diabetes 1999, 48:198-202.
6. McLellan A.C., Thornalley P.J., Benn J., Sonksen P.H. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. (Lond.) 1994, 87:21-29.
7. Wang H., Meng Q.H., Gordon J.R., Khandwala H., Wu L. Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus. Clin. Biochem. 2007, 40:1232-1239.
8. Lapolla A., Flamini R., Lupo A., et al. Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis. Ann. NY Acad. Sci. 2005, 1043:217-224.
9. Wang X., Desai K., Clausen J.T., Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int. 2004, 66:2315-2321.
10. Pedchenko V.K., Chetyrkin S.V., Chuang P., et al. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Diabetes 2005, 54:2952-2960.
11. Beisswenger P.J., Drummond K.S., Nelson R.G., Howell S.K., Szwergold B.S., Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005, 54:3274-3281.
12. Alexandraki K., Piperi C., Kalofoutis C., Singh J., Alaveras A., Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines. Ann. NY Acad. Sci. 2006, 1084:89-117.
13. Kristiansen O.P., Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54:S114-S124.
14. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diab. Care 2004, 27:813-823.
15. Berlanga J., Cibrian D., Guillen I., et al. Methylglyoxal administration induces diabetes-like microvascular changes. Clin. Sci. (Lond.) 2005, 109:83-95.
16. Fornoni A., Ijaz A., Tejada T., Lenz O. Role of inflammation in diabetic nephropathy. Curr. Diab. Rev. 2008, 4:10-17.
17. Wu C.C., Chen J.S., Lu K.C., et al. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin. Chim. Acta 2010, 411:700-704.
18. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 2009, 94:3171-3182.
19. Ko G.J., Kang Y.S., Han S.Y., et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant. 2008, 23:2750-2760.
20. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
21. Seckin D., Ilhan N., Ilhan N., Ertugrul S. Glycaemic control, markers of endothelial cell activation and oxidative stress in children with type 1 diabetes mellitus. Diab. Res. Clin. Pract. 2006, 73:191-197.
22. Aljada A., Friedman J., Ghanim H., et al. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism 2006, 55:1177-1185.
23. Schaumberg D.A., Glynn R.J., Jenkins A.J., et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 2005, 111:2446-2453.
24. Lin J., Glynn R.J., Rifai N., et al. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diab. Care 2008, 31:2338-2343.
25. Persson F., Rossing P., Hovind P., et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in patients with type 2 diabetes and microalbuminuria (IRMA 2) study. Scand. J. Clin. Lab. Invest. 2008, 68(8):731-738.
26. Han Y., Randell E., Vasdev S., et al. Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with type 1 diabetes. Mol. Cell. Biochem. 2007, 305:123-131.
27. Han Y., Randell E., Vasdev S., et al. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with type 1 diabetes. Clin. Biochem. 2009, 42:562-569.
28. Uribarri J., Peppa M., Cai W., et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am. J. Kidney Dis. 2003, 42:532-538.
29. Beisswenger P.J., Howell S.K., Nelson R.G., Mauer M., Szwergold B.S. Alpha- oxoaldehyde metabolism and diabetic complications. Biochem. Soc. Trans. 2003, 31(Pt 6):1358-1363.
30. Rosca M.G., Monnier V.M., Szweda L.I., Weiss M.F. Alterations in renal mitochondrial respiration in response to the reactive oxoaldehyde methylglyoxal. Am. J. Physiol. Ren. Physiol. 2002, 283:F52-F59.
31. Rosca M.G., Mustata T.G., Kinter M.T., et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol. Ren. Physiol. 2005, 289:F420-F430.
32. Liu B.F., Miyata S., Hirota Y., et al. Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int. 2003, 63:947-957.
33. Yan S.F., Ramasamy R., Schmidt A.M. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 2010, 106:842-853.
34. Navarro-González J.F., Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008, 19:433-442.
35. Navarro J.F., Mora C., Gómez M., Muros M., López-Aguilar C., García J. Influence of renal involvement on peripheral blood mononuclear cell expression behaviour of tumour necrosis factor-alpha and interleukin-6 in type 2 diabetic patients. Nephrol. Dial. Transplant. 2008, 23:919-926.
36. Rivero A., Mora C., Muros M., García J., Herrera H., Navarro-González J.F. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin. Sci. (Lond.) 2009, 116:479-492.
37. Vlassara H., Cai W., Crandall J., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl Acad. Sci. USA 2002, 99:15596-15601.
38. Welten A.G., Schalkwijk C.G., ter Wee P.M., Meijer S., van den Born J., Beelen R.J. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit. Dial. Int. 2003, 23:213-221.
39. Thorand B., Baumert J., Chambless L., et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler. Thromb. Vasc. Biol. 2006, 26:398-405.
40. Sattar N., Murray H.M., Welsh P., et al. Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly. Diabetologia 2009, 52:235-239. Prospective Study of Pravastatin in Elderly at Risk Trial Study Group.
41. Nakamura K., Yamagishi S., Adachi H., et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 2008, 76:52-56.